Reference

Literatura

• Fox AA; Collard CD; Shernan SK; et al. (2009).„Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting.”.Anesthesiology.110 (4): 738—47.PMC 2735337 .PMID 19326473.doi:10.1097/ALN.0b013e31819c7496. CS1 одржавање: Експлицитна употреба et al. (веза)
• Potthast R; Abbey-Hosch SE; Antos LK; et al. (2004). „Calcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-B/guanylyl cyclase-B.”.J. Biol. Chem.279 (47): 48513—9.PMID 15371450.doi:10.1074/jbc.M408247200. CS1 одржавање: Експлицитна употреба et al. (веза)
• Liew D; Schneider H; D'Agostino J; et al. (2004). „Utility of B-type natriuretic peptide as a screen for left ventricular dysfunction in patients with diabetes: response to Epshteyn et al.”.Diabetes Care.27 (3): 848; author reply 848—9.PMID 14988324.doi:10.2337/diacare.27.3.848. CS1 одржавање: Експлицитна употреба et al. (веза)
• Antos LK, Abbey-Hosch SE, Flora DR, Potter LR (2005). „ATP-independent activation of natriuretic peptide receptors.”.J. Biol. Chem.280 (29): 26928—32.PMID 15911610.doi:10.1074/jbc.M505648200. 
• Poreba R; Poczatek K; Gać P; et al. (2009). „SNP rs198389 (T-381 C) polymorphism in the B-type natriuretic peptide gene promoter in patients with atherosclerotic renovascular hypertension.”.Pol. Arch. Med. Wewn.119 (4): 219—24.PMID 19413180. CS1 одржавање: Експлицитна употреба et al. (веза)
• Koller KJ, Goeddel DV (1992). „Molecular biology of the natriuretic peptides and their receptors.”.Circulation.86 (4): 1081—8.PMID 1327579. 
• Fan D; Bryan PM; Antos LK; et al. (2005). „Down-regulation does not mediate natriuretic peptide-dependent desensitization of natriuretic peptide receptor (NPR)-A or NPR-B: guanylyl cyclase-linked natriuretic peptide receptors do not internalize.”.Mol. Pharmacol.67 (1): 174—83.PMID 15459247.doi:10.1124/mol.104.002436. CS1 одржавање: Експлицитна употреба et al. (веза)
• Pagel-Langenickel I, Buttgereit J, Bader M, Langenickel TH (2007). „Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy.”.J. Mol. Med.85 (8): 797—810.PMID 17429599.doi:10.1007/s00109-007-0183-4. 
• Rahmutula D, Cui J, Chen S, Gardner DG (2004).„Transcriptional regulation of type B human natriuretic Peptide receptor gene promoter: dependence on Sp1.”.Hypertension.44 (3): 283—8.PMID 15262909.doi:10.1161/01.HYP.0000136908.60317.92. 
• Humphray SJ; Oliver K; Hunt AR; et al. (2004).„DNA sequence and analysis of human chromosome 9.”.Nature.429 (6990): 369—74.PMC 2734081 .PMID 15164053.doi:10.1038/nature02465. CS1 одржавање: Експлицитна употреба et al. (веза)
• Hume AN; Buttgereit J; Al-Awadhi AM; et al. (2009).„Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux.”.Hum. Mol. Genet.18 (2): 267—77.PMC 2638773 .PMID 18945719.doi:10.1093/hmg/ddn354. CS1 одржавање: Експлицитна употреба et al. (веза)
• Schulz S (2005). „C-type natriuretic peptide and guanylyl cyclase B receptor.”.Peptides.26 (6): 1024—34.PMID 15911070.doi:10.1016/j.peptides.2004.08.027. 
• Tsuji T, Kunieda T (2005). „A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse.”.J. Biol. Chem.280 (14): 14288—92.PMID 15722353.doi:10.1074/jbc.C500024200. 
• Dickey DM, Yoder AR, Potter LR (2009).„A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation.”.J. Biol. Chem.284 (29): 19196—202.PMC 2740543 .PMID 19458086.doi:10.1074/jbc.M109.010777. 
• Nozohoor S; Nilsson J; Lührs C; et al. (2009). „B-type natriuretic peptide as a predictor of postoperative heart failure after aortic valve replacement.”.J. Cardiothorac. Vasc. Anesth.23 (2): 161—5.PMID 19167912.doi:10.1053/j.jvca.2008.11.006. CS1 одржавање: Експлицитна употреба et al. (веза)
• Hachiya R; Ohashi Y; Kamei Y; et al. (2007). „Intact kinase homology domain of natriuretic peptide receptor-B is essential for skeletal development.”.J. Clin. Endocrinol. Metab.92 (10): 4009—14.PMID 17652215.doi:10.1210/jc.2007-1101. CS1 одржавање: Експлицитна употреба et al. (веза)
• Gratacòs M; Costas J; de Cid R; et al. (2009). „Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment.”.Am. J. Med. Genet. B Neuropsychiatr. Genet.150B (6): 808—16.PMID 19086053.doi:10.1002/ajmg.b.30902. CS1 одржавање: Експлицитна употреба et al. (веза)
• Gerhard DS; Wagner L; Feingold EA; et al. (2004).„The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).”.Genome Res.14 (10B): 2121—7.PMC 528928 .PMID 15489334.doi:10.1101/gr.2596504. CS1 одржавање: Експлицитна употреба et al. (веза)
• Bartels CF; Bükülmez H; Padayatti P; et al. (2004).„Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux.”.Am. J. Hum. Genet.75 (1): 27—34.PMC 1182004 .PMID 15146390.doi:10.1086/422013. CS1 одржавање: Експлицитна употреба et al. (веза)
• van den Akker F (2001). „Structural insights into the ligand binding domains of membrane bound guanylyl cyclases and natriuretic peptide receptors.”.J. Mol. Biol.311 (5): 923—37.PMID 11556325.doi:10.1006/jmbi.2001.4922. 

Vidi još

Spoljašnje veze